DALLAS, June 14, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Insmed Inc. (Nasdaq:INSM). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at:
Insmed Inc. (INSM) is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases. The Company's primary focus is on the development of inhaled antibiotic therapy delivered via proprietary advanced pulmonary liposome technology in areas of high unmet need in lung diseases. INSM's lead product candidate ARIKACE is an inhaled antibiotic supported by positive phase II results for treating serious lung infections due to susceptible bacteria.
This newsletter has been helping traders make great investment decisions on INSM; click here for a 25% discount offer.
In the report, the analyst notes:
"INSM saw its stock rise more than 12% in Monday's trading after the Company last Friday announced positive data through six treatment cycles (72 weeks total duration) of its phase II clinical trial program for ARIKACE in cystic fibrosis (CF) patients with Pseudomonas lung infections. Predrag Minic, M.D., professor of Pediatrics and head of Pediatrics Pulmonology Department, Mother and Child Health Institute, Belgrade, Serbia, and co-lead investigator of the study, presented the data at the 34th European Cystic Fibrosis Conference in Hamburg, Germany."
"According to the release, the data demonstrated that ARIKACE, delivered once-daily for 28 consecutive days, followed by 56 days off-treatment, for a total of six cycles, resulted in statistically significant improvement in lung function that was sustained over a 72-week period."
To read the entire report visit:
See what investors are saying about INSM at
Get breaking news on INSM at
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit:
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.
CONTACT: Brian Johnson [email protected] 1-888-307-2850
